Merus Gets FDA Extension on Prescription Drug User Fee Act Goal Date for Zenocutuzumab to Feb. 4-March 2024-www.financetom.com

Merus Gets FDA Extension on Prescription Drug User Fee Act Goal Date for Zenocutuzumab to Feb. 4

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Merus Gets FDA Extension on Prescription Drug User Fee Act Goal Date for Zenocutuzumab to Feb. 4

Nov 6, 2024 6:40 AM

11:08 AM EST, 11/05/2024 (MT Newswires) -- Merus (MRUS) said Tuesday the US Food and Drug Administration has extended the Prescription Drug User Fee Act objective deadline for experimental NRG1+ cancer treatment zenocutuzumab.

The regulator moved the deadline to Feb. 4 to allow more time to review recent information Merus submitted, the company said.

Price: 51.25, Change: +0.02, Percent Change: +0.03

Previous page： Unipol chair hints that ING could be studying Popolare di Sondrio bid Next page： Update: AAR Shares Fall After Fiscal Q3 Revenue Misses Estimates

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Unipol chair hints that ING could be studying Popolare di Sondrio bid

Mar 28, 2025

MILAN (Reuters) - Unipol Chairman Carlo Cimbri said on Friday a foreign bank was studying a potential bid for Popolare di Sondrio to rival the one unveiled by Italy's BPER Banca. Insurer Unipol is the leading shareholder in both BPER and Pop Sondrio and has thrown its weight behind BPER's bid for Pop Sondrio. Speaking at the presentation of Unipol's...

Update: AAR Shares Fall After Fiscal Q3 Revenue Misses Estimates

Mar 28, 2025

02:22 PM EDT, 03/28/2025 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.) AAR (AIR) shares fell over 14% in recent trading Friday after the company's fiscal Q3 revenue missed analysts' estimates. The company reported fiscal Q3 adjusted earnings late Thursday of $0.99 per diluted share, up from $0.85 a year earlier. Analysts polled by...

Update: Wolfspeed Gets $192.1 Million in Tax Refunds Amid Reported Debt Refinancing Hurdle

Mar 28, 2025

02:20 PM EDT, 03/28/2025 (MT Newswires) -- (Updates with Bloomberg report on convertible bonds starting in third paragraph.) Wolfspeed ( WOLF ) said Friday it received $192.1 million in cash tax refunds through the Section 48D advanced manufacturing tax credit, including $186.5 million for fiscal 2023 and 2024, plus interest. Wolfspeed ( WOLF ) also said in a statement it...

VirTra Shares Are Down Today: What's Going On?

Mar 28, 2025

VirTra INC ( VTSI ). shares are trading lower Friday after the company reported worse-than-expected fourth-quarter financial results. What To Know: The company's revenue for the fourth quarter fell to $5.4 million, a 50% decline from the previous year's $10.9 million. Full-year revenue for 2024 also dropped by 32% to $26.4 million. Net income for the quarter turned negative, with...